Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM

In the backdrop of rapidly changing relapsed/refractory (RR) multiple myeloma (MM) treatment schema that mainly evolves around immunotherapies, it is easy to disregard more traditional drugs. Finding the best partner for pomalidomide, a potent third-generation immunomodulatory drug, is an important...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyunkyung, Byun, Ja Min, Yoon, Sung-Soo, Koh, Youngil, Yoon, Sock-Won, Shin, Dong-Yeop, Hong, Junshik, Kim, Inho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794080/
https://www.ncbi.nlm.nih.gov/pubmed/35085238
http://dx.doi.org/10.1371/journal.pone.0260113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794080/
https://www.ncbi.nlm.nih.gov/pubmed/35085238
http://dx.doi.org/10.1371/journal.pone.0260113

Ejemplares similares